Cost effectiveness of therapist delivered cognitive behavioural therapy and web-based self-management in irritable bowel syndrome: the ACTIB randomised trial

Published date: 6 July 2021

Additional Information: Funding Information: The project ACTIB (Assessing Cognitive–behavioural Therapy in Irritable Bowel syndrome)—a randomised controlled trial of clinical and cost-effectiveness of therapist-delivered cognitive–behavioural therapy and web-based self-management in irritable bowel syndrome—was funded by the National Institute for Health Research (NIHR) HTA Project: 11/69/02, with additional support from the NIHR Clinical Research Network. This paper represents independent research with some staff part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. Details of this study have previously been reported in https://eprints.soton.ac.uk/431211/1/Published_ACTIB_HTA_report_May_2019.pdf . PL was director of the National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) and a member of the Journals Library Board. TC reports grants from Guy’s and St Thomas’ Charity. She was a Faculty member, 3rd International Conference on Functional (Psychogenic) Neurological Disorders, Sept 2017, Edinburgh, Member of the IAPT Education and Training ERG (2016-), Member of the IAPT Outcomes and Informatics Meeting (2016), President of the British Association of Behavioural and Cognitive Psychotherapies (2012–2015) for which she did not receive payment. Workshops were delivered on medically unexplained symptoms, during the conduct of the study (money paid into KCL for future research). TC has a patent Background IP—manuals were developed prior to trial starting. SL and KG report grants from NIHR. The TSC Chair, PW, was a colleague of TC in the past but he has recently retired. RMM reports personal fees from training in IBS intervention for Central and North west London NHS Foundation Trust and University of East Anglia outside of the submitted work. Since this study was completed, she has received payment for consultancy to Mahana Therapeutics. Since this study was completed, a private company has signed a licence agreement with King’s College London with the view to bringing the Regul8 website product to the NHS and other international markets. RMM, HE, TC, AS, GOR will be beneficiaries of this licence through contracts with their respective Universities. The patient manual is background IP developed by CI's RMM and TC in previous work. Funding Information: PL was director of the National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) and a member of the Journals Library Board. TC reports grants from Guy’s and St Thomas’ Charity. She was a Faculty member, 3rd International Conference on Functional (Psychogenic) Neurological Disorders, Sept 2017, Edinburgh , Member of the IAPT Education and Training ERG (2016-), Member of the IAPT Outcomes and Informatics Meeting (2016), President of the British Association of Behavioural and Cognitive Psychotherapies (2012-2015) for which she did not receive payment. Workshops were delivered on medically unexplained symptoms, during the conduct of the study (money paid into KCL for future research). TC has a patent Background IP - manuals were developed prior to trial starting. SL and KG report grants from NIHR. The TSC Chair, PW, was a colleague of TC in the past but he has recently retired. RMM reports personal fees from training in IBS intervention for Central and North west London NHS Foundation Trust and University of East Anglia outside of the submitted work. Since this study was completed, she has received payment for consultancy to Mahana Therapeutics. Since this study was completed, a private company has signed a licence agreement with King’s College London with the view to bringing the Regul8 website product to the NHS and other international markets. RMM, HE, TC, AS, GOR will be beneficiaries of this licence through contracts with their respective Universities. The patient manual is background IP developed by CI's RMM and TC in previous work. No conflicts of interests for FB, RH, SL, SH, SW, PMc, NC, RL. Funding Information: The project ACTIB (Assessing Cognitive?behavioural Therapy in Irritable Bowel syndrome)?a randomised controlled trial of clinical and cost-effectiveness of therapist-delivered cognitive?behavioural therapy and web-based self-management in irritable bowel syndrome?was funded by the National Institute for Health Research (NIHR) HTA Project: 11/69/02, with additional support from the NIHR Clinical Research Network. This paper represents independent research with some staff part funded by the NIHR Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King?s College London. Details of this study have previously been reported in https://eprints.soton.ac.uk/431211/1/Published_ACTIB_HTA_report_May_2019.pdf. PL was director of the National Institute for Health Research (NIHR) Programme Grants for Applied Research (PGfAR) and a member of the Journals Library Board. TC reports grants from Guy?s and St Thomas? Charity. She was a Faculty member, 3rd International Conference on Functional (Psychogenic) Neurological Disorders, Sept 2017, Edinburgh, Member of the IAPT Education and Training ERG (2016-), Member of the IAPT Outcomes and Informatics Meeting (2016), President of the British Association of Behavioural and Cognitive Psychotherapies (2012?2015) for which she did not receive payment. Workshops were delivered on medically unexplained symptoms, during the conduct of the study (money paid into KCL for future research). TC has a patent Background IP?manuals were developed prior to trial starting. SL and KG report grants from NIHR. The TSC Chair, PW, was a colleague of TC in the past but he has recently retired. RMM reports personal fees from training in IBS intervention for Central and North west London NHS Foundation Trust and University of East Anglia outside of the submitted work. Since this study was completed, she has received payment for consultancy to Mahana Therapeutics. Since this study was completed, a private company has signed a licence agreement with King?s College London with the view to bringing the Regul8 website product to the NHS and other international markets. RMM, HE, TC, AS, GOR will be beneficiaries of this licence through contracts with their respective Universities. The patient manual is background IP developed by CI's RMM and TC in previous work. Publisher Copyright: © 2021, The Author(s). Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

Keywords: Cognitive behavioural therapy, Cost-effectiveness, Economic evaluation, Irritable bowel syndrome

Local EPrints ID: 449309

URI: http://eprints.soton.ac.uk/id/eprint/449309

DOI: doi:10.1186/s12876-021-01848-9

ISSN: 1471-230X

PURE UUID: ed3085a7-da11-4fd8-8ede-671e13a75fa8

ORCID for Hazel Everitt: orcid.org/0000-0001-7362-8403

ORCID for Paul Little: orcid.org/0000-0003-3664-1873

ORCID for Felicity L. Bishop: orcid.org/0000-0002-8737-6662

ORCID for Stephanie Hughes: orcid.org/0000-0003-4801-8245

Date deposited: 24 May 2021 16:31

Last modified: 12 Jul 2024 01:49